3-(2-vinylphenyl)propan-1-ol | 339177-03-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-vinylphenyl)propan-1-ol
• 英文别名: 3-(2-Ethenylphenyl)propan-1-ol
• CAS: 339177-03-6
• 化学式: C₁₁H₁₄O
• 分子量: 162.232
• InChiKey: BBGDCZYXLJUMAY-UHFFFAOYSA-N

物化性质

• 沸点：
  278.5±9.0 °C(Predicted)
• 密度：
  1.000±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(2-vinylphenyl)propan-1-ol 在 二氯二茂锆 吡啶 、 乙基氯化镁 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 2-异丙基-1-甲基-1,2,3,4-四氢萘
  参考文献：
  名称：

  Olefins Turned Alkylating Agents:  Diastereoselective Intramolecular Zr-Catalyzed Olefin Alkylations

  摘要：

  The first examples of intramolecular Zr-catalyzed electrophilic alkylation of aryl olefins are disclosed. Substituted carbo- and heterocycles are prepared efficiently and diastereoselectively.

  DOI：

  10.1021/ol017090c
• 作为产物：
  描述：

  3-(2-溴苯基)丙酸甲酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 4.0h， 生成 3-(2-vinylphenyl)propan-1-ol
  参考文献：
  名称：

  用于合成 4-aryltetralin-2-ols 和 5-aryltetrahydro-5H-benzo[7] annulen-7-ols 的级联分子内 Prins/Friedel-Crafts 环化

  摘要：

  用 BF 3 ·Et 2 O处理 2-(2-乙烯基苯基) 乙醛或 3-(2-乙烯基苯基) 丙醛导致分子内 Prins 反应，提供中间的苄基碳正离子，然后被各种富电子捕获芳烃通过 Friedel-Crafts 烷基化。这种级联 Prins/Friedel-Crafts 环化方案为获得具有药用价值的 4-aryltetralin-2-ol 和 5-aryltetrahydro-5 H - benzo[7]annulen-7-ol 衍生物铺平了道路。

  DOI：

  10.3762/bjoc.17.104

文献信息

• Macrocyclic Modulators of the Ghrelin Receptor
  申请人：Ocera Therapeutics, Inc.

  公开号：US20180110824A1

  公开（公告）日：2018-04-26

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了一种新颖的构象定义明确的大环化合物，已经证明是生长激素分泌素受体（GHS-R1a及其亚型、异构体和变体）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂，用于治疗和预防一系列医疗状况，包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、遗传疾病、过度增殖性疾病和炎症性疾病。
• Preparation of Oxocanes by Electrophilic Cyclizations of Unsaturated Alcohols in the Presence of Bis(collidine)halonium(I) Hexafluorophosphates
  作者：Christelle Mendès、Sylvie Renard、Mazin Rofoo、Marie-Claude Roux、Gérard Rousseau

  DOI：10.1002/ejoc.200390080

  日期：2003.2

  carbon chain with carbocyclic (phenyl and cyclopropane) and heterocyclic (epoxide and dioxolane) moieties were prepared and their cyclizations in the presence of bis(collidine)iodonium(I) and -bromonium(I) hexafluorophosphates as electrophiles were studied. Oxocanes were obtained in modest to good yields when a rigid cyclic moiety (cyclopropane or phenyl) was present in the chain, while yields of cyclizations

  制备了在 sp3-sp3 碳链中被碳环（苯基和环丙烷）和杂环（环氧化物和二氧戊环）部分取代的 7-Octen-1-ols 并在双（可力丁）碘鎓（I）和 -溴鎓存在下进行环化(I) 研究了六氟磷酸盐作为亲电试剂。当链中存在刚性环状部分（环丙烷或苯基）时，以适度到良好的产率获得氧杂环辛烷，而如果环状组分具有一定的柔韧性（二氧戊环），则环化的产率较低。使用带有环氧化物取代基的底物获得低产率，可能是因为存在可力丁导致稳定性问题。对于乙烯基环丙烷醇 12，我们主要观察到环丙烷环的开环和环化作用产生了四氢吡喃衍生物。(© Wiley-VCH Verlag GmbH &
• Some Observations Concerning the Thermally Induced Oxy-Ene Reaction
  作者：Gavin A. Schmid、Hans-Jürg Borschberg

  DOI：10.1002/1522-2675(20010228)84:2<388::aid-hlca388>3.0.co;2-p

  日期：2001.2.28

  Several examples of thermally induced intramolecular oxy-ene reactions leading to six- or five-membered rings are reported. The yields vary from poor to good, depending on the thermal lability of the substrate. Considering the high temperatures required to effect these transformations (several hours at ca. 250°), the observed diastereoselectivities favoring the trans-1,2-substituted cycloalkane derivatives

  报道了几个导致六元或五元环的热诱导分子内氧化烯反应的例子。取决于基材的热不稳定性，产量从差到好不等。考虑到实现这些转变所需的高温（在大约 250° 下几个小时），观察到的有利于反式 1,2-取代的环烷烃衍生物的非对映选择性非常好。在产品 26 的情况下，这些取代基在固态（X 射线证据）和溶液中都显示出更喜欢跨双轴取向，大概是为了避免在双赤道构象异构体中普遍存在的烯丙基应变。
• MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR
  申请人：TRANZYME PHARMA INC.

  公开号：US20130211045A1

  公开（公告）日：2013-08-15

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了一种新型构象定义的大环化合物，已经被证明是生长激素分泌肽受体（GHS-R1a和其亚型、同工异构体和变异体）的选择性调节剂。本文还描述了合成这些新化合物的方法。这些化合物可用作生长激素分泌肽受体的激动剂，以及用于治疗和预防一系列医学疾病，包括但不限于代谢和/或内分泌紊乱、胃肠道疾病、心血管疾病、肥胖和肥胖相关疾病、中枢神经系统疾病、遗传疾病、过度增生性疾病和炎症性疾病。
• Intermediates for macrocyclic modulators of the ghrelin receptor
  申请人：Tranzyme Pharma, Inc.

  公开号：EP2457893A1

  公开（公告）日：2012-05-30

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了新型构象明确的大环化合物，这些化合物已被证明是胃泌素受体（生长激素分泌受体，GHS-R1a 及其亚型、同工型和变体）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可作为胃泌素受体的激动剂以及治疗和预防一系列疾病的药物，这些疾病包括但不限于代谢和/或内分泌失调、胃肠道疾病、心血管疾病、肥胖和肥胖相关疾病、中枢神经系统疾病、遗传性疾病、过度增殖性疾病和炎症性疾病。